QS–immunotherapy clinical trial
tumor, pembrolizumab, Cancer
TUMOR, CANCER
We report the design and methods of a single-center study to investigate the efficacy and tolerability of a short course (or courses) of QS RT combined with the PD-1 inhibitor pembrolizumab. These standard-of-care treatments have the potential to act synergistically to improve response, and this study will investigate the combination of these two treatments in a novel sequence. The clinical hypothesis is that the delivery of one or more courses of QS RT in the proposed sequence with pembrolizumab is feasible and improves both response rates and duration of tumor response. This study will be conducted at the Wake Forest Baptist Comprehensive Cancer Center and is registered on 